Longitudinal microRNA profiles in breast cancer tissue and plasma: Associations with hormone receptors, response, and survival

Table 4 Univariate and multivariate Cox regression analysis of post- neoadjuvant chemotherapy clinicopathological factors and microRNA expression for overall survival in breast cancer patients

Variable	Univariate analysis		Multivariate analysis
	P value	Hazard ratios (95%CI)	P value	Hazard ratios (95%CI)
Age	0.530	0.980 (0.919-1.044)	0.532	0.959 (0.842-1.093)
Miller-Payne score (MPG 2, 3 vs 4, 5)	0.792	1.326 (0.162-10.840)	0.752	3.101 (0.003-3457.333)
Subtype (HR+ vs HR-)	0.897	1.113 (0.222-5.579)	0.044	0.015 (0.000-0.892)
miRNA-34a (high vs low)	0.827	1.169 (0.289-4.728)	0.600	0.485 (0.032-7.266)
miRNA-124a (high vs low)	0.642	1.394 (0.344-5.648)	0.654	1.666 (0.179-15.473)
miRNA-137 (high vs low)	0.739	0.790 (0.197-3.173)	0.284	0.188 (0.009-3.999)
miRNA-155 (high vs low)	0.974	1.023 (0.254-4.127)	0.999	3.143e-10 (0.000-Inf)
miRNA-373 (high vs low)	0.499	1.617 (0.401-6.515)	1.000	1.998 (0.000-Inf)
HR+: MiRNA-155 (high vs low)	-	-	0.999	7.324e+09 (0.000-Inf)
HR+: MiRNA-373 (high vs low)	-	-	1.000	9.290 (0.000-Inf)

Data represent the hazard ratios and 95% confidences intervals derived from Cox proportional hazards models. Univariate analysis evaluates the individual impact of each variable, while multivariate analysis adjusts for confounding factors to determine independent predictors of the outcome. Hazard ratios < 1 indicates a protective effect (decreased risk), while hazard ratios > 1 indicates an increased risk. MicroRNA (high vs low): Expression levels dichotomized based on median cutoff points. CI: Confidences interval; MPG: Miller-Payne grading; HR+: Hormone receptor positive; HR-: Hormone receptor negative.